| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2018 ( Subtotal = -$105,542 ) |
| | 2018 | 2016 | GLSYNTHESIS INC. | 298 HIGHLAND ST | WORCESTER | MA | 01602-2130 | WORCESTER | USA | R44GM109505 | Development of a fluorescence ABCG2 liposomal multidrug transporter assay | 000 | 2 | NIH | 3/23/2018 | -$105,542 |
| | 2018 | 2014 | GLSYNTHESIS INC. | 298 HIGHLAND ST | WORCESTER | MA | 01602-2130 | WORCESTER | USA | R43GM109505 | Development of a fluorescence liposomal ABCG2 Multidrug Transporter assay | 000 | 1 | NIH | 11/11/2017 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $0 ) |
| | 2017 | 2015 | GLSYNTHESIS INC. | 298 HIGHLAND ST | WORCESTER | MA | 01602-2130 | WORCESTER | USA | R43GM110858 | Production and inhibition assay for bile salt export protein | 000 | 1 | NIH | 4/27/2017 | $0 |
| | 2017 | 2015 | GLSYNTHESIS INC. | 298 HIGHLAND ST | WORCESTER | MA | 01602-2130 | WORCESTER | USA | R41GM110813 | A novel drug detection assay using fluorescent biosensor technology | 000 | 1 | NIH | 4/12/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $597,909 ) |
| | 2016 | 2016 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605-4306 | WORCESTER | USA | R44GM109505 | Development of a fluorescence ABCG2 liposomal multidrug transporter assay | 000 | 2 | NIH | 7/25/2016 | $597,909 |
|
| Issue Date FY: 2015 ( Subtotal = $1,980,965 ) |
| | 2015 | 2015 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605-4306 | WORCESTER | USA | R44TR000983 | Novel Antithrombotic Diadenosine Tetraphosphate Analogs | 000 | 6 | NIH | 7/1/2015 | $1,417,233 |
| | 2015 | 2015 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605-4306 | WORCESTER | USA | R43GM110858 | Production and inhibition assay for bile salt export protein | 000 | 1 | NIH | 12/29/2014 | $243,266 |
| | 2015 | 2015 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605-4306 | WORCESTER | USA | R41GM110813 | A novel drug detection assay using fluorescent biosensor technology | 000 | 1 | NIH | 1/9/2015 | $320,466 |
|
| Issue Date FY: 2014 ( Subtotal = $1,222,549 ) |
| | 2014 | 2014 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605-4306 | WORCESTER | USA | R43GM109505 | Development of a fluorescence liposomal ABCG2 Multidrug Transporter assay | 000 | 1 | NIH | 5/7/2014 | $363,564 |
| | 2014 | 2014 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605-4306 | WORCESTER | USA | R44TR000983 | Novel Antithrombotic Diadenosine Tetraphosphate Analogs | 000 | 5 | NIH | 7/3/2014 | $858,985 |
| | 2014 | 2012 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605 | WORCESTER | USA | R43AI100300 | Oral prodrug of a novel antiviral that blocks neuronal reactivation of HSV | 000 | 1 | NIH | 8/28/2014 | $0 |
|
| Issue Date FY: 2013 ( Subtotal = $1,358,080 ) |
| | 2013 | 2013 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605-4306 | WORCESTER | USA | R43AR063503 | A SOFT TOPICAL ANTIANDROGENIC DRUG | 000 | 1 | NIH | 8/28/2013 | $1 |
| | 2013 | 2013 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605-4306 | WORCESTER | USA | R43AR063503 | A SOFT TOPICAL ANTIANDROGENIC DRUG | 000 | 1 | NIH | 8/28/2013 | $237,356 |
| | 2013 | 2013 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605-4306 | WORCESTER | USA | R44TR000983 | Novel Antithrombotic Diadenosine Tetraphosphate Analogs | 001 | 4 | NIH | 7/24/2013 | $73,318 |
| | 2013 | 2013 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605-4306 | WORCESTER | USA | R44TR000983 | Novel Antithrombotic Diadenosine Tetraphosphate Analogs | 000 | 4 | NIH | 7/5/2013 | $1,047,405 |
|
| Issue Date FY: 2012 ( Subtotal = $1,715,514 ) |
| | 2012 | 2012 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605-4306 | WORCESTER | USA | R43AI100300 | Oral prodrug of a novel antiviral that blocks neuronal reactivation of HSV | 000 | 1 | NIH | 8/31/2012 | $300,000 |
| | 2012 | 2012 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605-4306 | WORCESTER | USA | R44AI051103 | PRECLINICAL DEVELOPMENT OF A NOVEL ANTIBACTERIAL FOR CLOSTRIDIUM DIFFICILE DISEAS | 000 | 6 | NIH | 2/28/2012 | $1,415,514 |
| | 2012 | 2010 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605 | WORCESTER | USA | R44HL088828 | NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATE ANALOGS | 000 | 3 | NIH | 7/20/2012 | $0 |
|
| Issue Date FY: 2011 ( Subtotal = $935,484 ) |
| | 2011 | 2011 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605-4306 | WORCESTER | USA | R44AI051103 | PRECLINICAL DEVELOPMENT OF A NOVEL ANTIBACTERIAL FOR CLOSTRIDIUM DIFFICILE DISEAS | 000 | 5 | NIH | 2/16/2011 | $935,484 |
|
| Issue Date FY: 2010 ( Subtotal = $1,891,168 ) |
| | 2010 | 2010 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605-4306 | WORCESTER | USA | R43AI091287 | ANALOGS OF GTP AS NOVEL INHIBITORS OF BACTERIAL C-DI-GMP-SYNTHESIZING ENZYMES | 000 | 1 | NIH | 6/7/2010 | $299,848 |
| | 2010 | 2010 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605-4306 | WORCESTER | USA | R44AI051103 | PRECLINICAL DEVELOPMENT OF A NOVEL ANTIBACTERIAL FOR CLOSTRIDIUM DIFFICILE DISEAS | 000 | 4 | NIH | 3/12/2010 | $620,114 |
| | 2010 | 2010 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605-4306 | WORCESTER | USA | R43GM093694 | SOLID STATE SYNTHESIS AND APPLICATIONS OF OLIGO(PHENYLENE-ETHYNES) | 000 | 1 | NIH | 6/14/2010 | $191,458 |
| | 2010 | 2010 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605-4306 | WORCESTER | USA | R44HL088828 | NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATE ANALOGS | 000 | 3 | NIH | 6/30/2010 | $779,748 |
|
| Issue Date FY: 2009 ( Subtotal = $2,206,945 ) |
| | 2009 | 2009 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605-4306 | WORCESTER | USA | R44AI068349 | HYBRID MOLECULES DESIGNED TO ENHANCE ANTIBIOTIC ACTIVITY | 000 | 6 | NIH | 6/3/2009 | $39,858 |
| | 2009 | 2009 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605-4306 | WORCESTER | USA | R44AG015259 | NOVEL DRUGS TO TREAT URINARY INCONTINENCE | 000 | 5 | NIH | 4/3/2009 | $894,091 |
| | 2009 | 2009 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605-4306 | WORCESTER | USA | R44HL088828 | NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATE ANALOGS | 000 | 2 | NIH | 8/5/2009 | $768,369 |
| | 2009 | 2009 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605-4306 | WORCESTER | USA | R44GM075397 | RAPID IN VITRO SUBSTRATE ASSAY FOR THE MULTI-DRUG RESISTANCE P-GLYCOPROTEIN | 000 | 3 | NIH | 12/19/2008 | $504,627 |
|
| Issue Date FY: 2008 ( Subtotal = $2,335,245 ) |
| | 2008 | 2008 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605 | WORCESTER | USA | R44GM075397 | RAPID IN VITRO SUBSTRATE ASSAY FOR THE MULTI-DRUG RESISTANCE P-GLYCOPROTEIN | 000 | 2 | NIH | 12/24/2007 | $573,551 |
| | 2008 | 2008 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605 | WORCESTER | USA | R44AG015259 | NOVEL DRUGS TO TREAT URINARY INCONTINENCE | 000 | 4 | NIH | 3/31/2008 | $794,658 |
| | 2008 | 2008 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605 | WORCESTER | USA | R44AI068349 | HYBRID MOLECULES DESIGNED TO ENHANCE ANTIBIOTIC ACTIVITY | 000 | 6 | NIH | 5/5/2008 | $967,036 |
|
| Issue Date FY: 2007 ( Subtotal = $3,126,530 ) |
| | 2007 | 2007 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605 | WORCESTER | USA | R43HL088828 | NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATE ANALOGS | 000 | 1 | NIH | 6/22/2007 | $333,166 |
| | 2007 | 2007 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605 | WORCESTER | USA | R44AI068349 | HYBRID MOLECULES DESIGNED TO ENHANCE ANTIBIOTIC ACTIVITY | 000 | 5 | NIH | 4/16/2007 | $939,605 |
| | 2007 | 2007 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605 | WORCESTER | USA | R43HL081992 | DIADENOSINE BORANOTETRAPHOSPH(ON)ATES AS ANTITHROMBOTIC DRUGS | 000 | 1 | NIH | 2/13/2007 | $299,670 |
| | 2007 | 2007 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605 | WORCESTER | USA | R44GM070035 | NON-SEDATING ATROPISOMERIC DRUGS FOR ATOPIC DISEASES | 000 | 3 | NIH | 6/21/2007 | $1,554,089 |
|
| Issue Date FY: 2006 ( Subtotal = $2,838,363 ) |
| | 2006 | 2006 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605 | WORCESTER | USA | R44AI051103 | PRECLINICAL DEVELOPMENT OF A NOVEL ANTIBACTERIAL FOR CLOSTRIDIUM DIFFICILE DISEAS | 000 | 3 | NIH | 4/10/2006 | $907,102 |
| | 2006 | 2006 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605 | WORCESTER | USA | R44GM070035 | NON-SEDATING ATROPISOMERIC DRUGS FOR ATOPIC DISEASES | 000 | 2 | NIH | 6/29/2006 | $992,986 |
| | 2006 | 2006 | GLSYNTHESIS, INC | ONE INNOVATION DRIVE | WORCESTER | MA | 01605 | WORCESTER | USA | R44AI068349 | HYBRID MOLECULES DESIGNED TO ENHANCE ANTIBIOTIC ACTIVITY | 000 | 4 | NIH | 4/20/2006 | $938,275 |
|
|
